

BO-008

## A SUSTAINED RELEASE TABLET OF PSEUDOEPHEDRINE AND KOB

## Chan-Ju Hwang<sup>1</sup>, Jong-Seong Kang<sup>1</sup>, Young-Ho Kim<sup>1</sup>, Yong-Ki Park<sup>2</sup> and <u>Cheong-Weon Cho<sup>1</sup></u>

- 1) College of Pharmacy, Chungnam National University, Daejeon, Korea
- College of Oriental Medicine, Dongguk University, Gyeongju, Republic of Korea

## **ABSTRACT**

Allergic rhinitis is one of inflammatory diseases affecting the nasal mucosa. Inflammatory of nasal mucosa is caused by hypersensitivity to certain allergen in nasal mucosa and is characterized by accumulation of mast cell, eosinophils and the release of various chemical mediators such as histamine, cytokines and chemokines. This inflammatory of nasal mucosa leads a convulsive cough, nasal congestion and snot and symptoms are reduced by antihistamine agents and decongestion agents such as pseudoephedrine. In this study, we prepared a combination drug containing both pseudoephedrine and KOB. KOB, which is extracted from herbal medicines, is being developed for treatment of allergic rhinitis and baicalin is considered as an index component. First of all, we determined drug interaction between pseudoephedrine and KOB. Then, we prepared formulation of pseudoephedrine and KOB, found optimized formulation. The aim of this study is to obtain an effective combination drug for treatment of rhinitis and nasal decongestion agent.

## Acknowledgments

This work was supported by the Priority Research Centers Program (2009-0093815) and the Basic Science Research Program (2009-0067380) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology.

Reproduced with permission of copyright owner. Further reproduction prohibited without permission.